ישראל -
עברית -
Ministry of Health
פולבניר
bioavenir ltd, israel - fulvestrant - תמיסה להזרקה - fulvestrant 50 mg/ml - fulvestrant
ישראל -
עברית -
Ministry of Health
טימנטין 3.2 ג'
glaxo smith kline (israel) ltd - clavulanic acid as potassium 200 mg/vial; ticarcillin disodium 3 g/vial - powder for solution for infusion - combinations of penicillins - timentin is an injectable antibiotic agent with a broad spectrum of bactericidal activity against a wide range of gram-positive and gram-negative, aerobic and anaerobic bacteria. the presence of clavulanate in the formulation extends the spectrum of activity of ticarcillin to include many beta-lactamase producing bacteria normally resistant to ticarcillin and other beta-lactam antibiotics. timentin is indicated for the treatment of infections in which susceptible organisms have been detected or are suspected. typical indications include: severe infections in hospitalised patients and proven or suspected infections in patients with impaired or suppressed host defences including: septicaemia, bacteraemia, peritonitis, intra-abdominal sepsis, post-surgical infections, bone and joint infections, skin and soft tissue infections, respiratory tract infections, serious or complicated renal infections (e.g. pyelonephritis), ear, nose and throat infections.
ישראל -
עברית -
Ministry of Health
טימנטין 3.2 ג'
glaxo smith kline (israel) ltd - clavulanic acid as potassium 200 mg/vial; ticarcillin as disodium 3 g/vial - powder for solution for infusion - combinations of penicillins - timentin is an injectable antibiotic agent with a broad spectrum of bactericidal activity against a wide range of gram-positive and gram-negative, aerobic and anaerobic bacteria. the presence of clavulanate in the formulation extends the spectrum of activity of ticarcillin to include many beta-lactamase producing bacteria normally resistant to ticarcillin and other beta-lactam antibiotics. timentin is indicated for the treatment of infections in which susceptible organisms have been detected or are suspected. typical indications include: severe infections in hospitalised patients and proven or suspected infections in patients with impaired or suppressed host defences including: septicaemia, bacteraemia, peritonitis, intra-abdominal sepsis, post-surgical infections, bone and joint infections, skin and soft tissue infections, respiratory tract infections, serious or complicated renal infections (e.g. pyelonephritis), ear, nose and throat infections.
ישראל -
עברית -
Ministry of Health
אונורג 200 מג
bristol, myers squibb (israel) limited, israel - azacitidine - טבליות מצופות פילם - azacitidine 200 mg - azacitidine
ישראל -
עברית -
Ministry of Health
אונורג 300 מג
bristol, myers squibb (israel) limited, israel - azacitidine - טבליות מצופות פילם - azacitidine 300 mg - azacitidine
ישראל -
עברית -
Ministry of Health
קרטיה
padagis israel agencies ltd, israel - acetylsalicylic acid - טבליות עם ציפוי אנטרי - acetylsalicylic acid 100 mg - acetylsalicylic acid - acetylsalicylic acid - the primary prevention of coronary heart disease in patients at increased risk and the secondary prevention of thrombotic cerebrovascular or cardiovascular disease.
ישראל -
עברית -
Ministry of Health
נמדטין 10 מג
teva israel ltd - memantine hydrochloride - טבליות מצופות פילם - memantine hydrochloride 10 mg - memantine
ישראל -
עברית -
Ministry of Health
נמדטין 20 מג
teva israel ltd - memantine hydrochloride - טבליות מצופות פילם - memantine hydrochloride 20 mg - memantine
ישראל -
עברית -
Ministry of Health
קסלג'אנז 5 מג
pfizer pharmaceuticals israel ltd - tofacitinib - טבליה - tofacitinib 5 mg - tofacitinib